Detalhe da pesquisa
1.
Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1.
Gene Ther
; 29(12): 698-709, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-35075265
2.
Recent Progress and Challenges in the Development of Antisense Therapies for Myotonic Dystrophy Type 1.
Int J Mol Sci
; 23(21)2022 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36362145
3.
Enhanced Delivery of Ligand-Conjugated Antisense Oligonucleotides (C16-HA-ASO) Targeting Dystrophia Myotonica Protein Kinase Transcripts for the Treatment of Myotonic Dystrophy Type 1.
Hum Gene Ther
; 33(15-16): 810-820, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35794764
4.
Stimulation of ENaC activity by rosiglitazone is PPARγ-dependent and correlates with SGK1 expression increase.
J Membr Biol
; 236(3): 259-70, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20740360